These results suggest that raltitrexed may enhance the antitumor effect of anlotinib on human ESCC cells by inhibiting Akt and Erk signaling pathways and affecting the phosphorylation of VEGFR-2. Here, AKT1 is linked to esophageal squamous cell carcinoma.